Fisher & Paykel Healthcare Corporation Ltd
NZX:FPH
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
21.55
38.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches NZD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FPH stock under the Base Case scenario is 23.1 NZD. Compared to the current market price of 36.2 NZD, Fisher & Paykel Healthcare Corporation Ltd is Overvalued by 36%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Fisher & Paykel Healthcare Corporation Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for FPH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Fisher & Paykel Healthcare Corporation Ltd., a leading provider of innovative medical devices and respiratory products, has carved a prominent niche in the global healthcare market. Founded in New Zealand in 1934, the company has evolved from a humble appliance manufacturer into a key player in respiratory care and sleep medicine. With a mission centered on improving patient outcomes, Fisher & Paykel leverages its strong research and development capabilities to create state-of-the-art products, such as its award-winning humidifiers and nasal mask systems, designed to support patients with respiratory issues and obstructive sleep apnea. The company boasts a diverse international presence, wit...
Fisher & Paykel Healthcare Corporation Ltd., a leading provider of innovative medical devices and respiratory products, has carved a prominent niche in the global healthcare market. Founded in New Zealand in 1934, the company has evolved from a humble appliance manufacturer into a key player in respiratory care and sleep medicine. With a mission centered on improving patient outcomes, Fisher & Paykel leverages its strong research and development capabilities to create state-of-the-art products, such as its award-winning humidifiers and nasal mask systems, designed to support patients with respiratory issues and obstructive sleep apnea. The company boasts a diverse international presence, with a robust distribution network that allows it to serve healthcare professionals and patients in over 120 countries.
For investors, Fisher & Paykel stands out not only for its continual focus on innovation but also for its stable financial performance. Throughout its history, the company has demonstrated resilience and adaptability, adeptly navigating market fluctuations and healthcare trends. With a strong balance sheet, a consistent track record of revenue growth, and a commitment to shareholder returns, Fisher & Paykel is well-positioned for future expansion, particularly as global healthcare demands rise. As the aging population and the increasing prevalence of chronic respiratory conditions drive market growth, investors may find Fisher & Paykel Healthcare a compelling opportunity, with its blend of innovative solutions and solid financial foundations paving the way for sustained success.
Fisher & Paykel Healthcare Corporation Ltd. is a New Zealand-based company primarily known for its innovative healthcare products and solutions, particularly in the fields of respiratory care, sleep apnea treatment, and surgical applications. The company's core business segments can be broadly categorized as follows:
-
Respiratory Care:
- This segment includes products and technologies designed to provide support for patients with respiratory conditions. Key offerings include humidification systems, interfaces (masks and nasal cannulas), and a range of devices that deliver positive airway pressure (PAP) therapy. The company targets both hospital and home care settings to improve patient outcomes in the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory ailments.
-
Obstructive Sleep Apnea (OSA):
- Fisher & Paykel Healthcare is well-known for its continuous positive airway pressure (CPAP) devices and accessories aimed at treating obstructive sleep apnea. This segment focuses on developing innovative solutions that enhance patient comfort and compliance, which can lead to better treatment outcomes.
-
Surgical & Other Applications:
- This segment encompasses a range of products used in surgical procedures and other medical environments. It includes a line of surgical humidifiers and related products that help maintain optimal air and humidity levels during surgeries, enhancing patient safety and recovery. This also covers areas like intensive care units (ICUs) and anesthesia.
-
Disposables:
- Fisher & Paykel Healthcare offers a variety of disposable products that are used in conjunction with its devices. This segment includes items such as masks, circuits, and other accessories necessary for delivering therapies in both hospital and home settings.
-
OEM and Licensed Products:
- The company also engages in original equipment manufacturing (OEM) and licensing agreements with other medical device companies, allowing it to leverage its technologies and innovations to create a broader impact in the healthcare sector.
Fisher & Paykel Healthcare emphasizes research and development to drive innovation across these segments, maintaining its position in a competitive market by continuously improving its product offerings and focusing on enhancing patient care.
Fisher & Paykel Healthcare Corporation Ltd (FPH) possesses several unique competitive advantages that distinguish it from its rivals in the healthcare equipment market, particularly in respiratory care and sleep apnea therapy. Here are some key advantages:
-
Innovation and R&D Focus: Fisher & Paykel Healthcare has a strong commitment to research and development, investing significantly in new product innovation. Their advanced technology in humidification and respiratory care has led to the development of unique, high-quality products that improve patient outcomes.
-
Specialization in Respiratory and Sleep Medicine: FPH has carved out a niche in respiratory and sleep medicine. This specialization allows the company to build deep expertise, foster close relationships with healthcare professionals, and better understand the needs of their target market.
-
Global Reach with Local Expertise: The company has a broad international presence, with sales in over 120 countries. This global reach is supported by local expertise that helps tailor products and marketing strategies to meet regional needs, enhancing competitiveness.
-
Strong Brand Recognition and Reputation: FPH’s products, particularly in humidification and non-invasive ventilation, have gained a strong reputation for quality and reliability among healthcare providers. This brand loyalty can translate to repeat business and customer retention.
-
Diverse Product Portfolio: The company offers a wide range of products, including devices and consumables for both hospital and home care settings. This diversification allows it to cater to various market segments and mitigate risks associated with dependency on a single product line.
-
Robust Clinical Evidence: Fisher & Paykel Healthcare actively engages in clinical studies to validate the efficacy of their products. This reliance on strong clinical evidence helps to reinforce their product claims and supports healthcare professionals' decision-making.
-
Solid Distribution Channels: FPH has established effective distribution networks that ensure product availability and support across multiple regions. Strong distributors can enhance service levels and customer satisfaction.
-
Commitment to Sustainability: Increasingly, healthcare providers are concerned with sustainability and environmental impact. Fisher & Paykel is focused on reducing waste and improving the sustainability of its products, which can provide an edge in markets that prioritize eco-friendly practices.
-
Strong Financial Position: FPH has demonstrated a solid financial performance characterized by healthy operating margins and consistent revenue growth. This financial stability allows for ongoing investments in innovation and market expansion.
-
Responsive Customer Service and Support: Effective customer service and technical support strengthen relationships with healthcare providers, ensuring that customers receive timely assistance and can maximize the use of their products.
By leveraging these competitive advantages, Fisher & Paykel Healthcare Corporation Ltd can effectively differentiate itself in a competitive marketplace, driving growth and sustaining its position as a leader in healthcare equipment.
Fisher & Paykel Healthcare Corporation Ltd (FPH) operates in the medical device industry, particularly in products for respiratory care and acute care. Here are some potential risks and challenges that FPH may face in the near future:
-
Regulatory Changes: The healthcare industry is heavily regulated. Changes in regulations or compliance requirements in different countries could increase costs and complicate market access.
-
Competition: The medical device market is competitive, with both large multinational corporations and smaller innovative firms. Increased competition can lead to price pressure, reduced market share, and the need for continuous innovation.
-
Supply Chain Disruptions: Global supply chains have been increasingly vulnerable to disruptions due to geopolitical tensions, natural disasters, or pandemics. Such disruptions can affect production capabilities and costs.
-
Technological Advancements: Rapid changes in technology require continuous investment in research and development. If FPH fails to keep pace with technological innovation, it may lose its competitive edge.
-
Market Demand Fluctuations: Demand for healthcare products can be volatile, especially in a post-pandemic world. An anticipated decline in demand for certain products after COVID-19 could impact revenue.
-
Intellectual Property Risks: Protecting intellectual property from infringement or theft is critical. FPH must continually monitor and enforce its patents to maintain its market position.
-
Economic Conditions: Global economic slowdowns can affect healthcare spending and budgets for hospitals and clinics, impacting FPH’s sales.
-
Cybersecurity Threats: As FPH develops more connected devices, the risk of cyberattacks increases, which could lead to data breaches and compromise patient safety.
-
Clinical Trials and Approvals: Any setbacks in clinical trials or delays in obtaining necessary approvals could hinder the introduction of new products and technology.
-
Dependency on Key Markets: High dependence on specific geographic markets can expose FPH to localized economic downturns or changes in healthcare policies.
By closely monitoring these risks and implementing robust strategies to mitigate them, Fisher & Paykel Healthcare Corporation can aim to secure its market position and ensure sustainable growth in the future.
Revenue & Expenses Breakdown
Fisher & Paykel Healthcare Corporation Ltd
Balance Sheet Decomposition
Fisher & Paykel Healthcare Corporation Ltd
Current Assets | 704.9m |
Cash & Short-Term Investments | 82m |
Receivables | 266.2m |
Other Current Assets | 356.7m |
Non-Current Assets | 1.6B |
PP&E | 1.3B |
Intangibles | 88.4m |
Other Non-Current Assets | 148.4m |
Current Liabilities | 385m |
Accounts Payable | 219.9m |
Other Current Liabilities | 165.1m |
Non-Current Liabilities | 137.6m |
Long-Term Debt | 92.9m |
Other Non-Current Liabilities | 44.7m |
Earnings Waterfall
Fisher & Paykel Healthcare Corporation Ltd
Revenue
|
1.7B
NZD
|
Cost of Revenue
|
-698.4m
NZD
|
Gross Profit
|
1B
NZD
|
Operating Expenses
|
-691m
NZD
|
Operating Income
|
353.4m
NZD
|
Other Expenses
|
-220.8m
NZD
|
Net Income
|
132.6m
NZD
|
Free Cash Flow Analysis
Fisher & Paykel Healthcare Corporation Ltd
NZD | |
Free Cash Flow | NZD |
FPH Profitability Score
Profitability Due Diligence
Fisher & Paykel Healthcare Corporation Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Fisher & Paykel Healthcare Corporation Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
FPH Solvency Score
Solvency Due Diligence
Fisher & Paykel Healthcare Corporation Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Fisher & Paykel Healthcare Corporation Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FPH Price Targets Summary
Fisher & Paykel Healthcare Corporation Ltd
According to Wall Street analysts, the average 1-year price target for FPH is 34.06 NZD with a low forecast of 26.26 NZD and a high forecast of 41.16 NZD.
Dividends
Current shareholder yield for FPH is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fisher & Paykel Healthcare Corp. Ltd. engages in the designing, manufacturing and marketing of medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. The firm offers its products across hospital and homecare settings. The Company’s hospital product group includes products used in invasive ventilation, noninvasive ventilation, nasal high flow therapy, and laparoscopic and open surgery. Its homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home, which include the Company’s continuous positive airway pressure (CPAP) therapy masks, as well as flow generators, interfaces, and data management technologies. The firm operates across Canada, the United States of America, Mexico, Costa Rica, the United Kingdom, Switzerland, India, Germany, Austria, Italy, Turkey, China, Hong Kong, Taiwan, Malaysia, Singapore and Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one FPH stock under the Base Case scenario is 23.1 NZD.
Compared to the current market price of 36.2 NZD, Fisher & Paykel Healthcare Corporation Ltd is Overvalued by 36%.